Evaluation of Molecular Residual Disease by a Fixed Panel in Resectable Colorectal Cancer.

ABSTRACT:

Purpose

Molecular residual disease (MRD) is a promising biomarker in colorectal cancer (CRC) for prognosis and guiding treatment, while the whole-exome sequencing (WES) based tumor-informed assay is standard for evaluating MRD based on circulating tumor DNA (ctDNA). In this study, we assessed the feasibility of a fixed-panel for evaluating MRD in CRC.

Materials and methods

Seventy-five patients with resectable stage I-III CRC were enrolled. Tumor tissues obtained by surgery, and preoperative and postoperative day 7 blood samples were collected. The ctDNA was evaluated using the tumor-agnostic and tumor-informed fixed assays, as well as the WES-based and panel-based personalized assays in randomly selected patients.

Results

The tumor-informed fixed assay had a higher p

SUBMITTER: Yang J 

PROVIDER: S-EPMC11491239 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature